JP2005515191A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2005515191A5 JP2005515191A5 JP2003546869A JP2003546869A JP2005515191A5 JP 2005515191 A5 JP2005515191 A5 JP 2005515191A5 JP 2003546869 A JP2003546869 A JP 2003546869A JP 2003546869 A JP2003546869 A JP 2003546869A JP 2005515191 A5 JP2005515191 A5 JP 2005515191A5
- Authority
- JP
- Japan
- Prior art keywords
- composition
- composition according
- ions
- mmol
- rubidium
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 claims description 29
- 206010052428 Wound Diseases 0.000 claims description 9
- 208000027418 Wounds and injury Diseases 0.000 claims description 6
- 230000035876 healing Effects 0.000 claims description 5
- BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical compound [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 claims description 4
- 229910001424 calcium ion Inorganic materials 0.000 claims description 4
- 229910001419 rubidium ion Inorganic materials 0.000 claims description 4
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 claims description 2
- IGLNJRXAVVLDKE-UHFFFAOYSA-N rubidium atom Chemical compound [Rb] IGLNJRXAVVLDKE-UHFFFAOYSA-N 0.000 claims description 2
- 239000011701 zinc Substances 0.000 claims description 2
- 229910052725 zinc Inorganic materials 0.000 claims description 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 4
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 claims 3
- PTFCDOFLOPIGGS-UHFFFAOYSA-N Zinc dication Chemical compound [Zn+2] PTFCDOFLOPIGGS-UHFFFAOYSA-N 0.000 claims 3
- 230000001684 chronic effect Effects 0.000 claims 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims 3
- 229910001414 potassium ion Inorganic materials 0.000 claims 3
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 claims 2
- 108090000862 Ion Channels Proteins 0.000 claims 2
- 102000004310 Ion Channels Human genes 0.000 claims 2
- 239000002202 Polyethylene glycol Substances 0.000 claims 2
- 239000002253 acid Substances 0.000 claims 2
- 239000001110 calcium chloride Substances 0.000 claims 2
- 229910001628 calcium chloride Inorganic materials 0.000 claims 2
- 229920001223 polyethylene glycol Polymers 0.000 claims 2
- 230000001737 promoting effect Effects 0.000 claims 2
- FGDZQCVHDSGLHJ-UHFFFAOYSA-M rubidium chloride Chemical compound [Cl-].[Rb+] FGDZQCVHDSGLHJ-UHFFFAOYSA-M 0.000 claims 2
- JIAARYAFYJHUJI-UHFFFAOYSA-L zinc dichloride Chemical compound [Cl-].[Cl-].[Zn+2] JIAARYAFYJHUJI-UHFFFAOYSA-L 0.000 claims 2
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 claims 1
- 102000000424 Matrix Metalloproteinase 2 Human genes 0.000 claims 1
- 108010016165 Matrix Metalloproteinase 2 Proteins 0.000 claims 1
- 102000001776 Matrix metalloproteinase-9 Human genes 0.000 claims 1
- 108010015302 Matrix metalloproteinase-9 Proteins 0.000 claims 1
- NPYPAHLBTDXSSS-UHFFFAOYSA-N Potassium ion Chemical compound [K+] NPYPAHLBTDXSSS-UHFFFAOYSA-N 0.000 claims 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims 1
- 239000011575 calcium Substances 0.000 claims 1
- 229910052791 calcium Inorganic materials 0.000 claims 1
- 230000005465 channeling Effects 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 239000012153 distilled water Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 239000000463 material Substances 0.000 claims 1
- 230000007935 neutral effect Effects 0.000 claims 1
- 229910052760 oxygen Inorganic materials 0.000 claims 1
- 239000001301 oxygen Substances 0.000 claims 1
- 239000001508 potassium citrate Substances 0.000 claims 1
- 229960002635 potassium citrate Drugs 0.000 claims 1
- QEEAPRPFLLJWCF-UHFFFAOYSA-K potassium citrate (anhydrous) Chemical compound [K+].[K+].[K+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O QEEAPRPFLLJWCF-UHFFFAOYSA-K 0.000 claims 1
- 235000011082 potassium citrates Nutrition 0.000 claims 1
- 229910052701 rubidium Inorganic materials 0.000 claims 1
- 229940102127 rubidium chloride Drugs 0.000 claims 1
- -1 rubidium chloride zinc chloride Chemical compound 0.000 claims 1
- 239000000126 substance Substances 0.000 claims 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims 1
- 239000011592 zinc chloride Substances 0.000 claims 1
- 235000005074 zinc chloride Nutrition 0.000 claims 1
- 238000003556 assay Methods 0.000 description 2
- 230000029663 wound healing Effects 0.000 description 2
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 230000024203 complement activation Effects 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 239000005414 inactive ingredient Substances 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 239000003642 reactive oxygen metabolite Substances 0.000 description 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US33433701P | 2001-11-29 | 2001-11-29 | |
| PCT/US2002/038175 WO2003045366A1 (en) | 2001-11-29 | 2002-11-27 | Treatment of wounds and compositions employed |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2005515191A JP2005515191A (ja) | 2005-05-26 |
| JP2005515191A5 true JP2005515191A5 (enExample) | 2006-01-26 |
Family
ID=23306754
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2003546869A Pending JP2005515191A (ja) | 2001-11-29 | 2002-11-27 | 創傷の治療及び使用する組成物 |
Country Status (8)
| Country | Link |
|---|---|
| US (5) | US20030133991A1 (enExample) |
| EP (1) | EP1461024A4 (enExample) |
| JP (1) | JP2005515191A (enExample) |
| AU (1) | AU2002359529B2 (enExample) |
| CA (1) | CA2468390A1 (enExample) |
| MX (1) | MXPA04005219A (enExample) |
| NZ (1) | NZ533252A (enExample) |
| WO (1) | WO2003045366A1 (enExample) |
Families Citing this family (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20040023937A1 (en) * | 2002-05-24 | 2004-02-05 | Greystone Medical Group, Inc. | Anti-cancer formulation |
| JP2006511585A (ja) * | 2002-12-23 | 2006-04-06 | グレイストーン メディカル グループ、インコーポレイテッド | 慢性創傷管理における活性酸素種の減少 |
| US20050175715A1 (en) * | 2003-08-25 | 2005-08-11 | Monroe Stephen H. | Cellular depolarization and regulation of matrix metalloproteinases |
| WO2006002326A2 (en) * | 2004-06-22 | 2006-01-05 | Greystone Medical Group, Inc. | Methods for treatment of wounds using time release compositions |
| US20070212342A1 (en) * | 2005-12-20 | 2007-09-13 | Swiss-American Products, Inc. | Protease compositions for the treatment of damaged tissue |
| US8795730B2 (en) * | 2006-01-31 | 2014-08-05 | David John Vachon | Compositions and methods for promoting the healing of tissue of multicellular organisms |
| US7687650B2 (en) | 2006-02-03 | 2010-03-30 | Jr Chem, Llc | Chemical compositions and methods of making them |
| PL1993569T3 (pl) | 2006-02-03 | 2014-11-28 | Obagi Cosmeceuticals Llc | Terapia przeciw starzeniu z użyciem kompozycji miedzi i cynku |
| US7897800B2 (en) | 2006-02-03 | 2011-03-01 | Jr Chem, Llc | Chemical compositions and methods of making them |
| WO2007143586A2 (en) * | 2006-06-01 | 2007-12-13 | Pharmaionx, Inc. | Composition for wound care and method of using same |
| US7867522B2 (en) | 2006-09-28 | 2011-01-11 | Jr Chem, Llc | Method of wound/burn healing using copper-zinc compositions |
| EP2152359A2 (en) | 2007-05-25 | 2010-02-17 | Compex Medical S.A. | Wound healing electrode set |
| ITBS20070178A1 (it) * | 2007-11-15 | 2009-05-16 | Paoli Ambrosi Gianfranco De | Composizione per uso farmaceutico e/o cosmetico e/o in forma di dispositivo medico per favorire processi di cicatrizzazione, per il trattamento di cicatrici ipertrofiche e per migliorare le proprieta' biomeccaniche della cute |
| US20100260863A1 (en) * | 2007-12-11 | 2010-10-14 | Monroe Stephen H | Composition of aqueous buffer solution for the treatment of cellular environment and ion channels and methods for using same |
| US8273791B2 (en) | 2008-01-04 | 2012-09-25 | Jr Chem, Llc | Compositions, kits and regimens for the treatment of skin, especially décolletage |
| CA2750636C (en) | 2009-01-23 | 2017-07-25 | Jr Chem, Llc | Rosacea treatments and kits for performing them |
| US20110008271A1 (en) * | 2009-07-13 | 2011-01-13 | Jr Chem, Llc | Rosacea treatments using polymetal complexes |
| US8952057B2 (en) | 2011-01-11 | 2015-02-10 | Jr Chem, Llc | Compositions for anorectal use and methods for treating anorectal disorders |
| GB201116523D0 (en) * | 2011-09-23 | 2011-11-09 | Systagenix Wound Man Ip Co Bv | Wound prognosis |
| EP2896963B1 (en) | 2011-01-31 | 2019-01-30 | Woundchek Laboratories B.V. | Wound prognosis |
| US9351995B1 (en) | 2011-04-29 | 2016-05-31 | Red Oax Holdings, LLC | Compositions and methods of enhancing wound healing |
| EP2734243A1 (en) * | 2011-07-20 | 2014-05-28 | 3M Innovative Properties Company | Dressing with ion-carrying composition |
| JP6133858B2 (ja) * | 2011-07-28 | 2017-05-24 | スリーエム イノベイティブ プロパティズ カンパニー | 創傷治癒組成物及び使用方法 |
| AU2013367193A1 (en) * | 2012-12-26 | 2015-07-16 | A-Z Ltd. | Wound healing accelerator |
| US10780114B2 (en) | 2015-06-12 | 2020-09-22 | Jfe Mineral Company, Ltd. | Therapeutic agent for skin wound or rough skin |
| DK3308794T3 (da) * | 2015-06-12 | 2022-11-07 | Jfe Mineral Co Ltd | Terapeutisk middel til sår eller ru hud |
| US10987380B2 (en) | 2016-12-09 | 2021-04-27 | Jfe Mineral Company, Ltd. | Hydrozincite containing zinc carbonate hydroxide hydrate and method of making |
| RU2636523C1 (ru) * | 2017-02-09 | 2017-11-23 | федеральное государственное бюджетное образовательное учреждение высшего образования "Воронежский государственный медицинский университет имени Н.Н. Бурденко" Министерства здравоохранения Российской Федерации (ФГБОУ ВО ВГМУ им. Н.Н. Бурденко Минздрава России) | Лекарственное средство для ускорения заживления ран, содержащее хлорид рубидия в виде порошка |
| CN116631510B (zh) * | 2022-10-28 | 2024-01-12 | 中国人民解放军军事科学院军事医学研究院 | 一种用于鉴别诊断克罗恩病和溃疡性结肠炎的装置 |
| WO2024196897A1 (en) * | 2023-03-22 | 2024-09-26 | Courtland Imel | Novel methods for increasing healing speed of human and animal wounds |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4600711A (en) * | 1982-08-18 | 1986-07-15 | The University Of Kentucky Research Foundation | Composition for topical and infusion treatment of wounds and burns |
| DE3416777C2 (de) * | 1984-05-07 | 1986-11-20 | Gödecke AG, 1000 Berlin | Pharmazeutische topische Zubereitungen |
| ATE191850T1 (de) * | 1992-11-06 | 2000-05-15 | Greystone Medical Group Inc | Eichenrindenextraktverwandte synthetische zubereitungen und verfahren zur verwendung |
| AUPN104895A0 (en) * | 1995-02-10 | 1995-03-09 | Lai, John | Methods of and preparations for the treatment of ailments and disorders |
| GB9905663D0 (en) * | 1999-03-12 | 1999-05-05 | Bristol Myers Squibb Co | Iodine preparation composition |
| US20020141964A1 (en) * | 2001-01-19 | 2002-10-03 | Patterson James A. | Composition for arresting the flow of blood and method |
| IL152453A (en) * | 2000-04-28 | 2008-03-20 | Biolife Llc | Hemostatic agent including an oxyacid salt |
| US6600057B2 (en) * | 2000-12-29 | 2003-07-29 | Kimberly-Clark Worldwide, Inc. | Matrix metalloproteinase inhibitors |
-
2002
- 2002-11-27 WO PCT/US2002/038175 patent/WO2003045366A1/en not_active Ceased
- 2002-11-27 JP JP2003546869A patent/JP2005515191A/ja active Pending
- 2002-11-27 US US10/305,713 patent/US20030133991A1/en not_active Abandoned
- 2002-11-27 AU AU2002359529A patent/AU2002359529B2/en not_active Ceased
- 2002-11-27 MX MXPA04005219A patent/MXPA04005219A/es unknown
- 2002-11-27 EP EP02794072A patent/EP1461024A4/en not_active Withdrawn
- 2002-11-27 NZ NZ533252A patent/NZ533252A/xx not_active IP Right Cessation
- 2002-11-27 CA CA002468390A patent/CA2468390A1/en not_active Abandoned
-
2005
- 2005-03-15 US US11/081,119 patent/US20060029682A1/en not_active Abandoned
-
2006
- 2006-09-20 US US11/523,869 patent/US20070009611A1/en not_active Abandoned
-
2007
- 2007-07-17 US US11/779,026 patent/US20070298121A1/en not_active Abandoned
-
2009
- 2009-09-23 US US12/565,244 patent/US20100196507A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2005515191A5 (enExample) | ||
| AT405403B (de) | Reinigung von von willebrand-faktor durch kationenaustauscherchromatographie | |
| TR200101903T2 (tr) | Yeni malonik asit türevleri, bunların preparasyon işlemleri. | |
| EP0784632A1 (de) | Verfahren zur gewinnung von hochreinem von willebrand-faktor | |
| DE60042153D1 (de) | Pharmauzetisch zusammensetzung nitratenquelle und ansäuerungsmitteln enthaltende zur behandlung von offenen wunden und verbrennungen | |
| ATE411280T1 (de) | Phenoxyessigsäure-derivate zur behandlung von störungen der atemwege | |
| EA200801073A1 (ru) | Фармацевтическая композиция, содержащая лактат, и ее применение | |
| JP2005515191A (ja) | 創傷の治療及び使用する組成物 | |
| KR101537774B1 (ko) | 악취제거제 조성물 및 그 제조방법 | |
| DE602005021770D1 (de) | Indol-1-yl-essigsäurederivate | |
| ATE406371T1 (de) | Wirkstoffe für die verminderung von amyloid precursor protein und die behandlung von schwachsinn, und deren verfahren der verwendung | |
| AT406373B (de) | Verfahren zur reinigung von faktor viii/vwf-komplex mittels kationenaustauscherchromatographie | |
| BR0312000A (pt) | Compostos, composições farmacêuticas, método para o tratamento ou profilaxia de doenças, e, uso dos compostos | |
| ATE415962T1 (de) | Verwendung von asiatsäure oder asiaticosid zur behandlung von krebs | |
| DE602004011022D1 (de) | Verfahren zur aufreinigung von (hydro)halogenkohlenstoffen | |
| JP2004531547A5 (enExample) | ||
| JP2003507389A5 (enExample) | ||
| WO2005123651A8 (fr) | L-2-(a-hydroxypentyle)benzoates, leur elaboration et leur utilisation | |
| ATE486599T1 (de) | Pharmazeutische zusammensetzung mit amlodipinbesilat und lisinoprildihydrat und herstellungsverfahren dafür | |
| DE50001654D1 (de) | Verfahren zur herstellung von polyvinylpyrrolidon-iod in wässriger lösung | |
| ATE283020T1 (de) | Biomaterial zur behandlung von zahnfäule | |
| US20060147484A1 (en) | Urushiol-induced contact dermatitis composition, method of use, and method of manufacture | |
| JP2005021875A (ja) | 水の酸化還元電位を維持する方法 | |
| ATE235909T1 (de) | Biologisch kompatible und biologisch abbaubare zubereitungen enthaltend hyaluronsäure und deren derivate zur behandlung von geschwüren im verdauungsapparat | |
| JP3519991B2 (ja) | 中性銀イオン水の製造方法 |